Highlights of Ophthalmology

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  52 (2024)
Volume  51 (2023)
Volume  50 (2022)
Volume  49 (2021)
Volume  48 (2020)
Volume  47 (2019)
Volume  46 (2018)
Volume  45 (2017)
Volume  44 (2016)
Volume  43 (2015)
Volume  42 (2014)
Volume  41 (2013)
Volume  40 (2012)
Volume  39 (2011)
Volume  38 (2009)
Related articles

VOLUME 41 , ISSUE 2ENG ( Apr-2013, 2013 ) > List of Articles

REVIEW ARTICLE

Rationale for the Use of Antiangiogenic Agents in the Management of Macular Edema due to Retinal Vein Occlusion

Roberto Gallego-Pinazo, Rosa Dolz-Marco, Cristina Marín-Lambíes, Manuel Díaz-Llopis

Citation Information : Gallego-Pinazo R, Dolz-Marco R, Marín-Lambíes C, Díaz-Llopis M. Rationale for the Use of Antiangiogenic Agents in the Management of Macular Edema due to Retinal Vein Occlusion. 2013; 41 (2ENG):20-21.

DOI: 10.5005/hoo-10101-41206

Published Online: 01-10-2020

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract
PDF Share
  1. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology. 2008;115:e47-54.
  2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-7.
  3. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-61.
  4. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412-6.
  5. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50: 1774-8.
  6. Czepluch FS, Olieslagers S, van Hulten R, Vöö SA, Waltenberger J. VEGFA- induced chemotaxis of CD16+ monocytes is decreased secondary to lower VEGFR-1 expression. Atherosclerosis. 2011;215:331-8.
  7. Meyer CH, Holz FG. Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Eye (Lond). 2011;25:661-72.
  8. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010;94:1215-8.
  9. Carneiro AM, Costa R, Falcão MS, et al. Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab. Acta Ophthalmol. 2011. doi: 10.1111/j.1755-3768.2011.02240.x.
  10. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008;16:791-9.
  11. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298-306.
  12. Brown DM, Campochiaro PA, Singh RP, et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124-33.
  13. Campochiaro PA, Heier JS, Feiner L, et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-12.
  14. Chang LK, Spaide RF, Klancnik JM, et al. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina. 2011;31:821-8.
  15. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol. 2010;150:310-4.
  16. Campochiaro PA, Hafiz G, Channa R, et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology. 2010;117(12):2387-94.
  17. Risard SM, Pieramici DJ, Rabena MD, et al. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31:1060-7.
  18. Sacu S, Pemp B, Weigert G, et al. Response of retinal vessels and retrobulbar hemodynamics to intravitreal anti-VEGF treatment in eyes with branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2011;52:3046-50.
  19. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118: 1594-602.
  20. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelvemonth outcomes of a phase III study. Ophthalmology. 2011;118:2041-9.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.